CD274 and neoplasm: Notably, the patient was resistant to PD-1 inhibitors (camrelizumab and sintilimab), and postoperative immunohistochemistry of ovarian metastases confirmed PD-L1 negativity, suggesting that immune therapy resistance might be linked to an immunosuppressive tumor microenvironment (TME).